The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

Expert Opinion on Biological Therapy

Volumn 10, Issue 12, 2010, Pages 1743-1752

  Swart, Joost Frans ^a,b,c   Barug, Daantje ^a   Möhlmann, Michelle ^a   Wulffraat, Nico M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Reade   (Netherlands)

Author keywords

anakinra; arthritis; IL 1 receptor antagonist; juvenile idiopathic arthritis; Still's disease; systemic

Indexed keywords

ADALIMUMAB; CANAKINUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE HEPATITIS; ANAPHYLAXIS; BRONCHITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG ABSORPTION; DRUG BINDING; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INFECTION; FRACTURE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HEADACHE; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; JUVENILE RHEUMATOID ARTHRITIS; LIVER CELL DAMAGE; NEPHROSIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; REVIEW; RHEUMATOID ARTHRITIS; SKIN ABSCESS; UPPER RESPIRATORY TRACT INFECTION; VISCERAL LEISHMANIASIS; VOMITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG LABELING; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; OFF-LABEL USE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78249256670     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.532785     Document Type: Review

References (52)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369(9563):767-78
2. Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008;35(2):343-8
3. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2
4. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201(9):1479-86
5. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146(5):598-604
6. Prieur AM, Stephan JL. Macrophage activation syndrome in rheumatic diseases in children. Rev Rhum Ed Fr 1994;61(6):447-51
7. Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 2004;50(3):689-98
8. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34(5):1133-8
9. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58(5):1505-15
10. Oen K, Malleson PN, Cabral DA, et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29(9):1989-99
11. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009;72(Suppl 1):20-5
12. Russo RA, Katsicas MM. Global damage in systemic juvenile idiopathic arthritis: preliminary early predictors. J Rheumatol 2008;35(6):1151-6
13. MMWR Data Source. 2003 Medical expenditure panel survey. MMWR 2007;56(01):4-7
14. Minden K, Niewerth M, Listing J, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol 2009;27(5):863-9
15. Minden K, Niewerth M, Listing J, et al. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63(7):836-42
16. Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000;43(11):2402-9
17. Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005;17(5):612-16
18. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63(12):1638-44
19. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009;36(5):1078-82
20. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28(2):129-37
21. Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005;5(5):683-90 (Pubitemid 40780551)
22. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371(9617):998-1006
23. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343(6256):341-6
24. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992;4(5):353-60
25. Nielsen JT. Handling of proteins in isolated and in vitro perfused proximal tubules from rabbit kidney. Dan Med Bull 1990;37(3):197-210
26. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003;74(1):85-94
27. Bendele A, McAbee T, Sennello G, et al. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999;42(3):498-506
28. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67(3):302-8
29. Irigoyen P, Olson J, Hom C, Ilowite N. Treatment of systemic onset juvenile idiopathic arthritis with anakinra. Case series. Pediatr Rheumatol Online J 2006;4(2):123-34
30. ®) in systemic juvenile idiopathic arthritis. Poster Abstract at PReS congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):32
31. Ohlsson V, Baildam E, Foster H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008;47(4):555-6
32. Pontikaki I, Gerloni V, Gattinara M, Fantini F. Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF. Poster Abstract at PReS congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):30
33. Wulffraat NM, De Jager W, Prakken B, Kuis W. Early effects of Anakinra in in corticosteroid naive SOJIA patients. Poster Abstract at PReS Congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):29
34. Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky mountain experience. J Clin Rheumatol 2009;15(4):161-4
35. Sandborg C, Holmes TH, Lee T, et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol 2006;33(11):2322-9
36. Quartier P, Allantaz F, Cimaz R, et al. Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS). Poster abstract at PReS congress London 2008. Pediatr Rheumatol 2008;6(Suppl 1):27
37. Canna S, Frankovich J, Higgins G, et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol Online J 2009;7:21
38. Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 2006;33(10):2081-4
39. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008;4(11):615-20
40. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31(10):2071-5
41. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2010 [Epub ahead of print]
42. Cron RQ, Beukelman T. Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010;8:23
43. Smith MY, Sobel RE, Wallace CA. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res (Hoboken) 2010;62(6):800-4
44. Neubert A, Wong IC, Bonifazi A, et al. Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res 2008;58(5-6): 316-22
45. Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999;48(1):15-18
46. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000;320(7227):79-82
47. Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002;324(7349):1312-13
48. Zajicek A. The National Institutes of Health and the Best Pharmaceuticals for Children Act. Paediatr Drugs 2009;11(1):45-7
49. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7, 527 patients. Arthritis Rheum 2003;48(10):2750-62
50. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42):1-229
51. Finckh A, Bansback N, Marra CA, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009;151(9):612-21
52. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40(7):1202-9